Paraguay to Purchase 1 Million COVID-19 Vaccine Doses

A U.S. company pioneering the development of a new class of immunotherapeutic vaccines, Vaxxinity, announced on June 21, 2021, a purchase order for its COVID-19 vaccine candidate, UB-612, with the Government of Paraguay.

The order was signed on June 16, 2021, by Dr. Julio Borba, Paraguay Minister of Health and Social Welfare. 

This COVID-19 vaccine purchase is contingent upon the issuance of an Emergency Use Authorization (EUA) by the Taiwanese Food and Drug Administration (TFDA), which will trigger a EUA in Paraguay. The UB-612 vaccine is expected to be delivered later in 2021.

Vaxxinity, in close collaboration with its partner, UBI-Asia, is completing a large Phase 2 clinical trial of UB-612 in Taiwan and will soon begin its Phase 2/3 efficacy clinical trial in India.

“Vaxxinity’s foundation is a commitment to democratizing healthcare worldwide,” said Lou Reese, co-founder and executive chairman of Vaxxinity, in a press release.

“Whether by cost, geography, healthcare infrastructure, discrimination, isolation, exclusion, economic or social status or legacy experience, vaccines to fight the global COVID-19 pandemic have not been distributed equitably to date. Vaxxinity has prioritized its focus on UB-612 while continuing the development of the other vaccines in its pipeline to rapidly develop, manufacture, and distribute vaccines to help combat the global COVID-19 pandemic in countries most in need.”

The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus. The UB-612 vaccine elicits broad humoral or cellular immune responses against several viral proteins to protect against COVID-19.

Mei Mei Hu, co-founder, and CEO of Vaxxinity, commented, “In addition, our UB-612 vaccine can be stored at the standard refrigeration range, enabling its distribution using cold-chain solutions readily available in the countries impacted by the COVID-19 pandemic the most.  This supports our mission to spearhead the democratization of global healthcare, which will lead to healthier, sustainable, and more productive communities across the world.”

Vaxxinity, Inc. is headquartered in Dallas, TX, with partners in the USA, Latin America, Europe, and Asia, the company’s proprietary Multitope technology platform has enabled the innovation of synthetic peptide vaccines designed to treat and prevent infectious diseases, including COVID-19, and chronic diseases, such as Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia.